Literature DB >> 4060198

[Diagnosis and therapy of Hodgkin's disease in Freiburg in Breisgau 1964 to 1976. 2. Results during the treatment period 1972-1976 compared with the period 1964-1971].

K Musshoff, V Weidkuhn, J Bammert, H U Felker.   

Abstract

The total group of patients with Hodgkin's disease submitted to primary treatment from May 1964 till December 1976 is divided with respect to diagnostics and therapy into a preponderantly clinically assessed group (CS) treated during the years of 1964 to 1971 (n = 190) and a preponderantly surgically assessed group (PS) treated during the years of 1972 to 1976 (n = 180). The first subgroup was treated with differently large irradiation fields and, in case of combined therapy, mostly with cyclophosphamide. The second subgroup was treated with extended fields, even until total lymphoid irradiation and, in case of drug administration, with primary combined chemotherapy (MOPP). The overall five-year remission rates of both subgroups (stages I to IV) have improved from 35.4% to 54.8% (P less than or equal to 0.001) and the five-year survival rates from 67.2% to 78.2% (P less than or equal to 0.001). If a complete remission was achieved, this was obtained, as far as judgeable, already at an earlier moment in the individual groups: e.g., in stage I with 95.5% after one year as against 94.1% after five years and in stage II with 91.3% after four years as against 72.9% after seven years. The prognostic differences of stages I and II and the histologic manifestations: lymphocytic predominance, nodular sclerosis, and mixed cellularity were equalized under the therapeutic measures of the intensive treatment period.

Entities:  

Mesh:

Year:  1985        PMID: 4060198

Source DB:  PubMed          Journal:  Strahlentherapie        ISSN: 0039-2073


  1 in total

1.  3-D reconstruction of anterior mantle-field techniques in Hodgkin's disease survivors: doses to cardiac structures.

Authors:  Dirk Vordermark; Ines Seufert; Franz Schwab; Oliver Kölbl; Margret Kung; Christiane Angermann; Michael Flentje
Journal:  Radiat Oncol       Date:  2006-04-20       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.